MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

American Journal of Surgical Pathology

Volumn 29, Issue 4, 2005, Pages 544-549

  Wasenius, Veli Matti ^a   Hemmer, Samuli ^a   Karjalainen Lindsberg, Marja Liisa ^b   Nupponen, Nina N ^a   Franssila, Kaarle ^b   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Laboratory of Molecular Oncology   (Finland)

Author keywords

Denaturing high performance chromatography; Juxtamembrane domain; MET oncogene; Thyroid carcinoma

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CLINICAL FEATURE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EXON; FOLLICULAR CARCINOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MET GENE; MISSENSE MUTATION; PAPILLARY CARCINOMA; PATHOGENESIS; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; AGED; CARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 15744373856     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000156103.37756.e2     Document Type: Article

References (28)

1. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
2. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802-804.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;15:472-480.
4. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas. Oncogene. 1992;7:2549-2553.
5. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1:147-154.
6. Di Renzo MF, Olivero M, Marione T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000;19:1547-1555.
7. Giordano S, Bardelli A, Zhen Z, et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci USA. 1997;94:13868-13872.
8. Giordano S, Maffe A, Williams TA, et al. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J. 2000;14:399-406.
9. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044-15049.
10. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA. 1998; 95:14417-14422.
11. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis [Review]. J Mol Med. 1996;74:505-513.
12. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 1997;94:11445-11450.
13. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19:4947-4953.
14. Lorenzato A, Olivero M, Patané S, et al. Novel somatic mutations oFthe MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002;62:7025-7030.
15. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272-6281.
16. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol. 2003; 4:339-347.
17. Moon Y-W, Weil RJ, Pack SD, et al. Missense mutation of the MET gene detected in human glioma. Mod Pathol. 2000;13:973-977.
18. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain oF the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59:307-310.
19. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements oF RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Cancer Res. 1998;154:237-247.
20. Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002;62:589-596.
21. Ruco LP, Stoppacciaro A, Ballarini F, et al. Met protein and hepatocyte growth Factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis [Review]. J Pathol. 2001;194:4-8.
22. Schmidt L, Duh F-M, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73.
23. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343-2350.
24. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
25. Wasenius V-M, Hemmer S, Kettunen E, et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003;9:68-75.
26. Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121: 145-154.
27. Vigna E, Gramaglia D, Longati P, et al. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation oF TPR-MET. Oncogene. 1999;18:4275-4281.
28. Yu Y, Merlino G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res. 2002;62:2951-2956.